Oversight Committee


David Anderson, PhD

David Anderson, PhD

Chief Scientific Officer, Ivogen (Subsidiary of Nanova Biomaterials, Inc.)

David has deep expertise in target-based drug discovery and development and personalized molecular diagnostics in inflammation/immunology, oncology, microbiology, and bone biology. He is an accomplished leader in medical research and product development with experience as a research scientist, director of research, and executive leader in the pharmaceutical industry and biotechnology.

As an entrepreneur, he built and managed innovative drug discovery and development companies. He was a leader of teams responsible for the development of five approved drugs (Procrit®, Leustatin®, and Revlimid® for hematology/oncology indications and Zubrin® for veterinary arthritis use, and Surfaxin® for respiratory distress syndrome), nine INDs, and two Personalized Diagnostic products for rheumatoid arthritis (AVISE-PG® & AVISE-MCV®).  David effectively managed human, technical, and financial resources, represented start-up companies to venture capital and banking firms to raise over $150M, partnered with world-class biopharmaceutical companies for $150M in milestone/equity payments, received over $4M in SBIR grants, and conducted research leading to the first $1B biotechnology product, Procrit® (Johnson & Johnson).

He has established translational research with world-class academic investigators to enhance and compliment expertise for successful research and product development. He has served as a consultant for numerous companies, VC and investment firms and as an SAB member.

David received a Ph.D. from The University of Missouri in medical microbiology and immunology and has held academic positions at the University of Colorado Health Sciences Center, The Scripps Research Institution and Graceland University. He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory/immunomodulatory and cancer drugs, and has refereed articles for peer-reviewed journals including Science, The Journal of Rheumatology, and Journal of Pharmacology and Experimental Therapeutics. David has an outstanding record of scientific publications and presentations with 32 peer-reviewed publications and more than 50 presentations/abstracts. Also, he has received a number of awards and five patents for his innovative research.

Bob Basore

Bob Basore

Independent Business Consultant

Bob has over 25 years of diverse healthcare experience in both large and small companies. He has previously held positions of VP R&D, VP Strategy and Portfolio Management, VP International Marketing, VP Strategic Alliances as well as multiple VP Sales and Marketing positions. He has developed and successfully executed strategic, commercial and healthcare economic plans for both established and aspiring pharmaceutical and diagnostics businesses.

Charles W. (Bill) Caldwell, PhD, MD

Charles W. (Bill) Caldwell, PhD, MD

Sr. Medical Fellow, Eli Lilly

Dr. Caldwell earned his undergraduate degree in medical technology from Arkansas State University and his PhD in Microbiology and Immunology as well as Medical Degree from the University of Missouri. He has over 100 research publications and 2 patents for his work. He also has a long history of biomedical translational research and the Wallace H. Coulter Foundation.

Until recently, he was the endowed CRC Missouri Chair in Cancer Research and Director of the Ellis Fischel Cancer Center. He currently holds a position as Professor Emeritus of Pathology and Anatomical Sciences, and is Senior Medical Fellow with Eli Lilly and Company involved in diagnostic and experimental medicine in the oncology area.

Elias Caro, MS

Elias Caro, MS

VP Technology Development, Wallace H. Coulter Foundation

Elias is VP of Technology Development in charge of the grant programs in biomedical research at the Wallace H. Coulter Foundation where he joined in 2006. From 1998 to 2006 in Beckman Coulter, he occupied positions of increasing responsibility as Vice President of Diagnostic R&D, President of the Biomedical Research Division and Executive Vice President in charge of International Diagnostics Commercial Operations and Worldwide Life Sciences. From 1985 to 1998 for Coulter Corporation, he managed several international operations in Latin America, France, Belgium and Japan. Elias holds a Bachelor degree in Industrial Engineering, Masters in Business and Polymer Science and is an AIMBE fellow.

Brian Clevinger, PhD

Brian Clevinger, PhD

Managing Director, Prolog Ventures

Brian L. Clevinger, Ph.D. is a managing director of Prolog Ventures, an early stage venture capita lfirm focusing on life science start-ups. He has more than 30 years of experience with all phases of commercial development of life science technology. His experience includes working with university faculty to determine business potential of research programs, developing commercialization strategies and business plans, negotiating technology licensing agreements, raising capital and providing management leadership ranging from Board to CEO-level.

His investment activities at Prolog emphasize biotechnology and medical devices. Either in his role as a venture capitalist or working for a venture capitalist, he has been involved in the funding of over 30 biomedical start-ups and has been an advisor to several more.

Gregory J. Della Rocca, MD, PhD, FACS

Gregory Della Rocca, MD, PhD, FACS

Section Head, Orthopaedic Trauma, Duke University

Dr. Della Rocca earned his bachelor's degree from Cornell University in 1992. He completed a doctoral degree from Duke University in 1998 and earned his medical degree the following year. He completed his residency training at Washington University/Barnes-Jewish Hospital in St. Louis, Missouri, in 2004, and a fellowship in Orthopedic Trauma at Seattle's Harborview Medical Center in 2005. He joined MU as co-director of Orthopedic Trauma that year.

He is now the Associate Professor of Orthopedic Surgery at the University Of Missouri School Of Medicine.

Christopher (Chris) Fender, MS

Christopher (Chris) Fender, MS

Director of the University of Missouri Office of Technology Management and Industry Relations

Chris Fender, Director of the Office of Technology Management and Industry Relations at the University of Missouri, Columbia, is responsible for stimulating the development and commercialization of advanced technology and transforming University of Missouri intellectual property into successful business enterprise. On behalf of MU, Fender interacts with faculty, community, business and state government leaders to promote University of Missouri intellectual property. As a U.S. Patent co-inventor, Fender understands the value of intellectual property and the invention to commercialization process.

James (Jim) Gilkerson, DVM

James (Jim) Gilkerson, DVM

Distinguished Corporate Fellow and Clinical Advisor, Boston Scientific

James Gilkerson is a Distinguished Corporate Fellow at Boston Scientific in St. Paul, Minnesota. Dr. Gilkerson has been employed in the Research and Development department of BSC CRM since June 1990, most recently as a Clinical Advisor for the Guidant Cardiac Rhythm Management Division. From 1987-1990 he was Manager of Preclinical Studies and Attending Veterinarian.

Dr. Gilkerson joined CPI in December of 1986 as Clinical Administrator in the Clinical Studies Department. He received his B.S. and D.V.M. degrees from the University of Missouri and is a regular member of the Heart Rhythm Society, Heart Failure Society of America, and the American Veterinary Medical Association.

Randel Frazier, MS

Randel Frazier, MS

Board of Directors, Sealantis LTD

Randel Frazier, a highly accomplished Global R&D leader, has directed and advised multibillion-dollar Fortune 500 operating units and smaller joint venture collaborations, startup incubator companies, and engineering universities in senior executive, board and advisory board roles. Leveraging 25+ years of experience driving the development and launch of 20 to 50 products annually, Randel has led international R&D, built new sites from the ground up and expanded partnering and joint venture opportunities. Continuously shaping collaborative development relationships in internal corporate business units, external companies, incubator groups, universities and government entities, Randel delivers new technologies and products that meet changing global customer and markets’ needs.

Randel holds a Master of Science in Mechanical Engineering from Stanford University and a Bachelor of Science in Engineering from Massachusetts Institute of Technology (MIT). As Head of R&D and Chief Technology Officer at Medtronic’s Covidien Group, Randel directed new medical device product development in the US, Europe, Asia and Latin America. Randel held prior R&D and Medical Affairs leadership roles with Covidien, Tyco International, and Valleylab. He also held earlier R&D and Engineering roles with Colorado MedTech, Cobe Laboratories, Storagetek Corporation, 3M Corporation and United Technologies Corporation. He has been a Board Member with MindUP, a digital health incubator, Medtronic joint venture in Haifa, Israel, and an Advisory Board Member for a Covidien supported startup in women’s health. Randel has also served as an Industrial Advisory Board Member for the St. Louis Museum of Science, Southern Illinois University’s School of Engineering, and University of Colorado’s Mechanical Engineering school.

Jerry Parker, PhD

Jerry Parker, PhD

Associate Dean for Research; University of Missouri School of Medicine. Co-Director, Operations, Integration, and Evaluation, University of Missouri Institute for Clinical and Translational Science

Jerry Parker has an extensive background in academic leadership. He is currently Associate Dean for Research and Clinical Professor of Physical Medicine and Rehabilitation. Prior, he was Associate Chief of Staff for Research and Development at the Harry S. Truman Memorial Veteran's Hospital; He also has served as Director, Behavioral Health at the HSTMVH which involved administration of a comprehensive behavioral health program, including inpatient psychiatry, addictions treatment, day treatment, outpatient psychiatry, homelessness program, and a network of clinics across the state of Missouri.

In these practitioner and behavioral health administrator roles, he developed a keen sensitivity to the challenges involved in the delivery of health care services and the implementation of evidence-based practices, as well as a deep understanding of the need for clinical and translational research in these areas.

Jinglu Tan, PhD

Jinglu Tan, PhD

James C. Dowell Professor and chair of the Biological Engineering Department at the University of Missouri

Jinglu Tan is James C. Dowell Professor and Chair of the Department of Biological Engineering at University of Missouri-Columbia; Director for the Division of Food Systems and Bioengineering in the College of Agriculture, Food, and Natural Resources (CAFNR); Co-Director of the Bioprocessing and Biosensing Center of the MU Food for the 21st Century Program.

Tan is also former Interim Chair for the Department of Chemical Engineering in the College of Engineering; past Interim Chair, Department of Food Science; past Interim Chair, Hotel & Restaurant Management Program; and past Director of Graduate Studies, Department of Biological Engineering, at the University of Missouri-Columbia.

Bill Turpin

Bill Turpin

President and CEO of the Missouri Innovation Center in Columbia, Missouri

Bill is President and CEO of the Missouri Innovation Center in Columbia, Missouri. Bill works with faculty and students from the University of Missouri and local entrepreneurs to start and grow technology-based companies. MIC also operates the MU Life Sciences Incubator with over 20 clients commercializing new technologies in areas such as medical devices, pharmaceuticals, animal health, agriculture, and alternative energy.

Bill has over 30 years of experience as an entrepreneur in the computer software industry. Over the course of Bill's career, he has identified and led the market in significant technology shifts, including Windows, the Internet, and 3D virtual worlds. One of his startups pioneered the use of dynamically created web pages and invented the JavaScript programming language. He has been the founding CEO of 4 startups and a senior executive at respected public companies including Netscape and Borland.

Over his career, Bill has financed, acquired, and sold a variety of high-tech companies. He has successfully secured investments from prominent venture capitals firms, including Kleiner Perkins, and was an Entrepreneur in Residence at Redpoint Ventures. He participated in the ground breaking Netscape IPO in 1995. And along the way, Bill has served as a mentor and angel investor to many Silicon Valley startups.

Bill has a BS in Electrical Engineering from the University of Missouri and an Executive MBA from the University of Texas.

Alan Wright, MD, MSPH

Alan Wright, MD, MPH

Chief Medical Officer - Roche Diagnostics Corporation

As the Chief Medical Officer for Roche Diagnostics Corporation, Alan serves as our clinical spokesperson and lead counsel on everything from the policy to the practice of diagnostic medicine. With his extensive history in the managed care, pharmaceutical and biotechnology industries, Alan is well-versed in the changing landscape of healthcare including emerging trends and technologies, regulatory and legislative hurdles, payer challenges and the growing relevance of diagnostics with the advent of outcome-based reimbursement.

Alan’s Medical and Scientific Affairs organization serves as the clinical partner to Roche customers by managing both Investigator Initiated and Roche Sponsored Studies, scientific consulting, advisory boards, PACE and CEU education, an on-site applications lab, Visiting Scientist Program and Fellows Program. By cultivating relationships with other industry thought leaders, Alan helps align our diagnostic development to Roche’s focus in infectious disease, cardiology, oncology, women’s health, inflammation and blood screening.

Alan brings with him medical and scientific leadership experience from his work at Miraca Life Sciences, Caris Life Sciences, Star Pharmaceuticals, Caremark, Inc. and AdvancePCS. He earned his medical degree from University of Pennsylvania School of Medicine and a masters of public health degree from Johns Hopkins School of Public Health and Hygiene.